Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Anti-platelet aggregation polypeptide

An anti-platelet aggregation, platelet aggregation technology, applied in the field of medicine and biology, can solve problems such as not seen

Active Publication Date: 2020-12-25
FIRST AFFILIATED HOSPITAL OF KUNMING MEDICAL UNIV
View PDF5 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The new polypeptide 6X sequence involved in the present invention has not been reported so far

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Anti-platelet aggregation polypeptide
  • Anti-platelet aggregation polypeptide
  • Anti-platelet aggregation polypeptide

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0036] Example 1: 6X inhibits anti-CD9-induced human platelet aggregation in vitro

[0037] The effect of 6X on anti-CD9-induced platelet aggregation was evaluated by optical turbidimetry. Healthy volunteers signed informed consent for blood donation and were given certain nutritional subsidies. Venous whole blood was collected, apheresis platelets were separated by Kunming Blood Center, and apheresis platelets were collected in the Hematology Department of the First Affiliated Hospital of Kunming Medical University. The implementation steps are as follows:

[0038] (1) DMSO was dissolved 6X, and the 6X concentration was adjusted to 25mM; an equal volume of DMSO was added to the control group.

[0039] (2) Wash platelets: Take 1 mL of human apheresis platelets stored at 25°C with constant temperature and shaking in a 1.5 mL centrifuge tube, add EDTA with a final concentration of 5 mM and 0.1 U / mL Apyrase (prepared with normal saline to prevent platelet aggregation during cen...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
Login to View More

Abstract

The invention discloses an anti-platelet aggregation polypeptide 6X. The polypeptide is the polypeptide 6X composed of 10 amino acids, has a sequence of SEQ ID NO:1, and has the molecular weight of 1103.19 Da; the sequence is Thr-Asn-Leu-Thr-Ser-Arg-Asn-Leu-Gly-Gln; the polypeptide is not limited to inhibition of platelet aggregation induced by an Fc[gamma]RIIA specific activator anti-CD9; and thepolypeptide can be used for exploring the influence of the polypeptide and other platelet activators (collagen, arachidonic acid, ADP, epinephrine, ristomycin and the like) on the effects and relatedfunctions of platelets, and can also be used for monitoring existing antiplatelet treatment.

Description

technical field [0001] The invention relates to the technical field of medicine and biology, in particular to an anti-platelet aggregation polypeptide 6X. Background technique [0002] Heparin-induced thrombocytopenia (Heparin-Induced Thrombocytopenia, HIT) is a life-threatening rare adverse drug reaction (incidence rate about <0.1%- 7.0%) [1] . 30%-50% of HIT patients have a high risk of thrombosis, and thrombosis is the main cause of death [2] . Although the introduction of new anticoagulant drugs, the incidence of HIT has not decreased, mainly because there is no drug that can replace heparin for the immediate treatment of acute deep vein thrombosis, arterial thrombosis or cardiopulmonary bypass during surgery or intensive care [3] . Patients who are highly suspected or diagnosed with HIT should stop taking heparin immediately and receive anticoagulant therapy such as direct thrombin inhibitors in time [4] . However, these alternative drugs not only bring bleedi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K7/06A61K38/08A61P7/04A61P9/00
CPCC07K7/06A61P7/04A61P9/00A61K38/00
Inventor 叶雨佳孟照辉
Owner FIRST AFFILIATED HOSPITAL OF KUNMING MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com